Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 138,153 | 87,630 | 61,385 | 90,285 | 71,625 |
| Receivables | 135,862 | 158,429 | 137,673 | 109,726 | 99,412 |
| Inventories | 222,098 | 206,465 | 196,667 | 191,464 | 172,188 |
| Other current assets | 0 | 6,530 | 0 | 0 | 0 |
| TOTAL | $511,173 | $466,512 | $402,655 | $399,563 | $351,814 |
| Non-Current Assets | |||||
| PPE Net | 65,010 | 65,057 | 69,509 | 57,501 | 57,710 |
| Intangibles | 4,160 | 4,162 | 4,021 | 4,057 | 3,982 |
| Other Non-Current Assets | 84,841 | 88,511 | 92,502 | 97,259 | 97,063 |
| TOTAL | $154,011 | $157,730 | $166,032 | $158,817 | $158,755 |
| Total Assets | $665,184 | $624,242 | $568,687 | $558,380 | $510,569 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 20,523 | 22,519 | 24,021 | 29,769 | 20,607 |
| Accrued Expenses | 48,561 | 40,466 | 28,827 | 43,902 | 31,560 |
| Other current liabilities | N/A | 2,647 | N/A | N/A | N/A |
| TOTAL | $73,541 | $69,541 | $56,490 | $74,941 | $53,498 |
| Non-Current Liabilities | |||||
| Long Term Debt | 193,584 | 69,330 | 70,084 | 73,397 | 72,527 |
| Deferred Revenues | N/A | N/A | N/A | 143 | 143 |
| Other Non-Current Liabilities | 0 | 0 | 90 | 940 | 1,315 |
| TOTAL | $201,318 | $77,381 | $81,011 | $85,114 | $83,652 |
| Total Liabilities | $274,859 | $146,922 | $137,501 | $160,055 | $137,150 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 231,773 | 238,159 | 237,998 | 238,631 | 238,734 |
| Common Shares | 24 | 24 | 24 | 24 | 24 |
| Retained earnings | -116,325 | -161,653 | -211,032 | -247,460 | -281,679 |
| Other shareholders' equity | -170 | -90 | -188 | -148 | 0 |
| TOTAL | $390,325 | $477,320 | $431,186 | $398,325 | $373,419 |
| Total Liabilities And Equity | $665,184 | $624,242 | $568,687 | $558,380 | $510,569 |